Therapeutic angiogenesis for ischemic cardiovascular disease

Journal of Molecular and Cellular Cardiology

Volumn 33, Issue 3, 2001, Pages 379-393

  Freedman, Saul Benedict ^a,b   Isner, Jeffrey M ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Angiogenesis: VEGF; Vascular endothelial growth factor

Indexed keywords

ANGIOGENIC FACTOR; ANGIOPOIETIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; HEPARIN; NITRATE; RECOMBINANT ACIDIC FIBROBLAST GROWTH FACTOR; RECOMBINANT BASIC FIBROBLAST GROWTH FACTOR; RECOMBINANT CYTOKINE; RECOMBINANT PROTEIN; RECOMBINANT VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ADVENTITIA; ANGINA PECTORIS; ANGIOGENESIS; CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; EXERCISE; GENE TRANSFER; HUMAN; HYPOTENSION; HYPOXIA; INTRACORONARY INFUSION; ISCHEMIC HEART DISEASE; LIMB ISCHEMIA; NEOPLASM; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PERICARDIUM; PERIPHERAL VASCULAR DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEINURIA; QUALITY OF LIFE; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SUSTAINED RELEASE PREPARATION;

EID: 0034978322     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1006/jmcc.2000.1329     Document Type: Review

References (144)

1. Tumor angiogenesis: Therapeutic implications
2. Therapeutic angiogenesis: A single intra-arterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hindlimb model
3. 165
4. 165 following intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia
5. Direct myocardial revascularization and angiogenesis - How many patients might be eligible?
6. Differentiation of endothelium
7. Induction of vasculogenesis and hematopoiesis in vitro
8. In vitro differentiation of murine embryonic stem cells: New approaches to old problems
9. Isolation of putative progenitor endothelial cells for angiogenesis
10. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization
11. Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization
12. Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization
13. Monocyte activation in angiogenesis and collateral growth in the rabbit hindlimb
14. Tissue responses to ischemia: Local and remote responses for preserving perfusion of ischemic muscle
15. Similarities between the oxygen-sensing mechanisms regulating the expression of vascular endothelial growth factor and erythropoietin
16. Hypoxic induction of vascular endothelial growth factor (VEGF) in human epithelial cells is mediated by increases in mRNA stability
17. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1
18. Transcriptional regulation of the rat vascular endothelial growth factor gene by hypoxia
19. Stabilization of vascular endothelial growth factor mRNA by hypoxia and hypoglycemia and co-regulation with other ischemia-induced genes
20. Therapeutic angiogenesis following arterial gene transfer of vascular endothelial growth factor in a rabbit model of hindlimb ischemia
21. Failure of blood-island formation and vasculogenesis in Flk-1 deficient mice
22. Molecular analysis of blood vessel formation and disease
23. Role of flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium
24. Hyperplasia of lymphatic vessels in VEGFC transgenic mice
25. Functional upregulation of the vascular endothelial growth factor receptor KDR by hypoxia
26. VEGF, flk-1, and flt-1 expression in a rat myocardial infarction model of angiogenesis
27. Hypoxia induces vascular endothelial growth factor in cultured human endothelial cells
28. Vascular endothelial growth factor165 gene transfer augments circulating endothelial progenitor cells in human subjects
29. VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells
30. 165 in patients with inoperable coronary disease
31. Angiogenesis
32. Therapeutic angiogenesis
33. Cardiac angiogenesis and gene therapy: A strategy for myocardial revascularization
34. Mechanisms of angiogenesis and arteriogenesis
35. Arterial gene transfer of acidic fibroblast growth factor for therapeutic angiogenesis in vivo: Critical role of secretion signal in use of naked DNA
36. Intracoronary gene transfer of fibroblast growth factor-5 increases blood flow and contractile function in an ischemic region of the heart
37. Intracoronary gene transfer of fibroblast growth factor-4 increases regional contractile function and responsiveness to adrenergic stimulation in heart failure
38. Age-dependent impairment of angiogenesis
39. Rescue of diabetes related impairment of angiogenesis by intramuscular gene theray with adeno-VEGF
40. -1-Mice
41. Interindividual heterogeneity in the hypoxic regulation of VEGF: Significance for the development of the coronary artery collateral circulation
42. Genetic heterogeneity of angiogenesis in mice
43. Angiogenesis and vasculogenesis as therapeutic strategies for postnatal neovascularization (Perspective)
44. Stem cell therapy and gene transfer for regeneration
45. VEGF improves myocardial blood flow but produces EDRF-mediated hypotension in porcine hearts
46. Lower-extremity edema associated with gene transfer of naked DNA vascular endothelial growth factor
47. Preclinical and clinical studies with recombinant human basic fibroblast growth factor
48. A double-blind, placebo-controlled, phase II study of basic fibroblast growth factor in the treatment of intermittent claudication
49. Pharmacodynamics of basic fibroblast growth factor: Route of administration determines myocardial and systemic distribution
50. Long-term persistence of plasmid DNA and foreign gene expression in mouse muscle
51. Direct intramuscular gene transfer of naked DNA encoding vascular endothelial growth factor augments collateral development and tissue perfusion
52. Increased expression of direct gene transfer into skeletal muscles observed after acute ischemic injury in rats
53. 125I-labeled basic fibroblast growth factor (bFGF) favor intramyocardial delivery
54. Collateral circulation of the heart
55. Basic fibroblast growth factor enhances myocardial collateral flow in a canine model
56. Effects of chronic systemic administration of basic fibroblast growth factor on collateral development in the canine heart
57. Comparative effects of basic fibroblast growth factor and vascular endothelial growth factor on coronary collateral development and arterial response to injury
58. Intracoronary basic fibroblast growth factor enhances myocardial collateral perfusion in dogs
59. Effect of basic fibroblast growth factor on myocardial angiogenesis in dogs with mature collateral vessels
60. Basic fibroblast growth factor improves myocardial function in chronically ischemic porcine hearts
61. Basic fibroblast growth factor in a porcine model of chronic myocardial ischemia: A comparison of angiographic, echocardiographic and coronary flow parameters
62. Intrapericardial delivery of fibroblast growth factor-2 induces neovascularization in a porcine model of chronic myocardial ischemia
63. Effects of acidic fibroblast growth factor on normal and ischemic myocardium
64. Extracardiac to coronary anastomoses support regional left ventricular function in dogs
65. Angiogenic potential of perivascularly delivered aFGF in a porcine model of chronic myocardial ischemia
66. VEGF administration in chronic myocardial ischemia in pigs
67. Vascular endothelial growth factor in chronic myocardial ischemia
68. Intramyocardial but not intravenous vascular endothelial growth factor improves regional perfusion in hibernating porcine myocardium
69. Angiogenic-induced enhancement of collateral blood flow to ischemic myocardium by vascular endothelial growth factor in dogs
70. Intramyocardial gene therapy with naked DNA encoding vascular endothelial growth factor improves collateral flow to ischemic myocardium
71. Catheter-based gene transfer of VEGF utilizing electromechanical LV mapping accomplishes therapeutic angiogenesis: Pre-clinical studies in swine
72. Percutaneous electromechanical mapping demonstrates efficacy of pVGI.1 (VEGF2) in an animal model of chronic myocardial ischemia
73. Biologic bypass with the use of adenovirus-mediated gene transfer of the complementary deoxyribonucleic acid for vascular endothelial growth factor 121 improves myocardial perfusion and function in the ischemic porcine heart
74. Focal angiogen therapy using intramyocardial delivery of an adenovirus vector coding for vascular endothelial growth factor 121
75. Adenoviral-mediated gene transfer induces sustained pericardial VEGF expression in dogs: Effect on myocardial angiogenesis
76. Evaluation of the effects of intramyocardial injection of DNA expressing vascular endothelial growth factor (VEGF) in a myocardial infarction model in the rat - Angiogenesis and angioma formation
77. VEGF gene delivery to myocardium: Deleterious effects of unregulated expression
78. Cather-based myocardial gene transfer utilizing nonfluoroscopic electromechanical left ventricular mapping
79. Percutaneous endocardial gene therapy: Patterns of in vivo gene expression related to regional myocardial delivery
80. 121 offers equivalent gene delivery and protein expression compared to a surgical-based transepicardial injection approach
81. Randomized placebo-controlled clinical study of percutaneous catheter-based left ventricular endocardial gene transfer of VEGF-2 for myocardial angiogenesis in patients with chronic myocardial ischemia
82. Critical limb ischmia: Nothing to give at the office?
83. Arterial gene transfer for naked DNA for therapeutic angiogenesis: Early clinical results
84. Treatment of thromboangiitis obliterans (Buerger's disease) by intramuscular gene transfer of vascular endothelial growth factor: Preliminary clinical results
85. 165 as sole therapy for myocardial ischemia
86. Nonfluoroscopic, in vivo navigation and mapping technology
87. Electromechanical characterization of chronic myocardial infarction in the canine coronary occlusion model
88. 165 gene transfer for therapeutic angiogenesis in chronic myocardial ischemia
89. Effects of short-term treatment of hyperlipidemia on coronary vasodilator function and myocardial perfusion in regions having substantial impairment of baseline dilator reserve
90. Magnetic resonance mapping demonstrates benefits of VEGF-induced myocardial angiogenesis
91. Coronary angiogenesis: Detection in vivo with MR imaging sensitive to collateral neocirculation - Preliminary study in pigs
92. Coronary collateral development in swine after coronary artery occlusion
93. Use of synchrotron radiation microangiography to assess development of small collateral arteries in a rat model of hindlimb ischemia
94. Induction of neoangiogenesis in ischemic myocardium by human growth factors: First clinical results of a new treatment of coronary heart disease
95. The stimulation of neoangiogenesis in the ischemic human heart by the growth factor FGF: First clinical results
96. First angiogenic treatment of coronary heart disease by FGF-1: Long-term results after 3 years
97. Induction of myocardial neoangiogenesis by human growth factors. A new therapeutic option in coronary heart disease
98. Local perivascular delivery of basic fibroblast growth factor in patients undergoing coronary bypass surgery: Results of a phase 1 randomized, double-blind, placebo-controlled trial
99. Results of a phase 1 open label dose escalation study of intracoronary and intravenous basic fibroblast growth factor (rFGF-2) in patients (pts) with severe ischemic heart disease: 6 months follow-up
100. Intracoronary administration of recombinant human vascular endothelial growth factor (rhVEGF) to patients with coronary artery disease
101. Intracoronary basic fibroblast growth factor (FGF-2) in patients with severe ischemic heart disease: Results of a phase 1 open label dose escalation study
102. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 improves stress and rest myocardial perfusion abnormalities in patients with severe symptomatic chronic coronary artery disease
103. Review of preclinical and clinical results with vascular endothelial growth factors for therapeutic angiogenesis
104. Effect of intracoronary recombinant human vascular endothelial growth factor on myocardial perfusion: Evidence for a dose-dependent effect
105. Final results of the VIVA trial of rhVEGF for human therapeutic angiogenesis
106. Meeting highlights: Highlights of the 48th scientific sessions of the american college of cardiology
107. VIVA trial: One year follow up
108. Results from late-breaking clinical trials sessions at ACCIS 2000 and ACC 2000
109. Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease: Preliminary clinical results
110. 165: Results of complete patient cohort in phase 1/2 clinical trial
111. Intraoperative multiplane transesophageal echocardiograpy for guiding direct myocardial gene transfer of vascular endothelial growth factor in patients with refractory angina pectoris
112. Mechanism of impaired myocardial function during progressive coronary stenosis in conscious pigs: Hibernation versus stunning?
113. Hibernating myocardium
114. Current diagnostic techniques of assessing myocardial viability in patients with hibernating and stunned myocardium
115. 121 cDNA to individuals with clinically significant severe coronary artery disease
116. 121
117. Effective gene transfer of phVEGF-2 for therapeutic angiogenesis in chronic myocardial ischemia as assessed by NOGA™ left ventricular electromechanical mapping
118. The effects of VEGF-2 gene therapy on rest and stress myocardial perfusion: Results of serial SPECT imaging
119. Transmyocardial laser revascularisation in patients with refractory angina: A randomised controlled trial
120. Transmyocardial laser revascularisation compared with continued medical therapy for treatment of refractory angina pectoris: A prospective randomised trial
121. Comparison of transmyocardial revascularization with medical therapy in patients with refractory angina
122. Transmyocardial revascularization with a carbon dioxide laser in patients with end-stage coronary artery disease
123. 2 laser in patients with refractory angina pectoris: Clinical results from the Norwegian randomized trial
124. Vascular endothelial growth factor/ vascular permeability factor produces nitric oxide-dependent hypotension
125. Vascular endothelial growth factor (VEGF)/vascular permeability factor (VPF) augments nitric oxide release from quiescent rabbit and human vascular endothelium
126. Nitric oxide synthase modulates angiogenesis in response to tissue ischemia
127. Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1
128. VEGF gene delivery to muscle: Potential role of vasculogenesis in adults
129. Vascular endothelial growth factor in ocular fluids of patients with diabetic retinopathy and other retinal disorders
130. Influence of vascular endothelial growth factor on diabetic retinopathy
131. Angiogenesis inhibitors endostatin and TNP-470 reduce intimal neovascularization and plaque growth in apolipoprotein E-deficient mice
132. Stent endothelialization: Time course, impact of local catheter delivery, feasibility of recombinant protein administration, and response to cytokine expedition
133. 165 inhibits thrombus formation and intimal thickening
134. Local delivery of vascular endothelial growth factor accelerates reendothelialization and attenuates in-timal hyperplasia in balloon-injured rat carotid artery
135. 165 gene transfer
136. Arterial gene therapy for inhibiting restenosis in patients with claudication undergoing superficial femoral artery angioplasty
137. Catheter-mediated vascular endothelial growth factor gene transfer to human coronary arteries after angioplasty
138. In vivo gene transfer and expression in normal uninjured blood vessels using replication-deficient recombinant adenovirus vectors
139. Synergistic effect of vascular endothelial growth factor and basic fibroblast growth factor on angiogenesis in vivo
140. Tie2 receptor ligands, angiopoietin-1 and angiopoietin-2, modulate VEGF-induced postnatal neovascularization
141. Hypercholesterolemia attenuates angiogenesis but does not preclude augmentation by angiogenic cytokines
142. Endothelium dysfunction in the coronary circulation
143. Therapeutic potential of ex vivo expanded endothelial progenitor cells for myocardial ischemia